7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Vestibulocochlear Nerve Diseases D000160 1 associated lipids
Acromegaly D000172 6 associated lipids
Actinobacillus Infections D000189 4 associated lipids
Actinomycosis D000196 2 associated lipids
Addison Disease D000224 3 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Hyperplasia, Congenital D000312 2 associated lipids
Albuminuria D000419 18 associated lipids
Alzheimer Disease D000544 76 associated lipids
Angina, Unstable D000789 14 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Geoffroy V et al. High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. 2002 Mol. Cell. Biol. pmid:12167715
Uemura H et al. Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers. 2002 J. Endocrinol. pmid:12176675
Ragab AA et al. Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells. 2002 Am. J. Physiol., Cell Physiol. pmid:12176725
Whyte MP et al. Osteoprotegerin deficiency and juvenile Paget's disease. 2002 N. Engl. J. Med. pmid:12124406
Krane SM Genetic control of bone remodeling--insights from a rare disease. 2002 N. Engl. J. Med. pmid:12124412
Ziolkowska M et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. 2002 Arthritis Rheum. pmid:12124857
Campagnuolo G et al. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. 2002 Arthritis Rheum. pmid:12124878
Sakata M et al. Osteoprotegerin levels increased by interleukin-1beta in human periodontal ligament cells are suppressed through prostaglandin E(2) synthesized de novo. 2002 Cytokine pmid:12126649
Petersson M et al. Oxytocin stimulates proliferation of human osteoblast-like cells. 2002 Peptides pmid:12126740
Cundy T et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. 2002 Hum. Mol. Genet. pmid:12189164
Williamson E et al. Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction. 2002 J. Immunol. pmid:12244151
Lee SK et al. 1,25(OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts. 2002 J. Immunol. pmid:12193704
Ferrer Cañabate J et al. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?]. 2002 An Med Interna pmid:12244784
Chen XW et al. Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. 2002 Biochem. Biophys. Res. Commun. pmid:12150965
Katagiri T and Takahashi N Regulatory mechanisms of osteoblast and osteoclast differentiation. 2002 Oral Dis pmid:12108759
Lee SK and Lorenzo JA Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures. 2002 Bone pmid:12110442
Shioi A et al. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. 2002 Circ. Res. pmid:12114316
Lipton A et al. Serum osteoprotegerin levels in healthy controls and cancer patients. 2002 Clin. Cancer Res. pmid:12114435
Fujita T et al. SPARC stimulates the synthesis of OPG/OCIF, MMP-2 and DNA in human periodontal ligament cells. 2002 J. Oral Pathol. Med. pmid:12201246
Juji T et al. A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders. 2002 J. Bone Miner. Metab. pmid:12203031
Grisar J et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. 2002 J. Rheumatol. pmid:12136902
Hofbauer LC et al. Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. 2002 Eur. J. Endocrinol. pmid:12153751
Inoue D and Matsumoto T [Recent advances in basic research of bone metabolism]. 2002 Nippon Rinsho pmid:11979916
Suzuki Y et al. [Bone destruction and bone loss in rheumatoid arthritis--mechanism, prevention and treatment]. 2002 Nippon Rinsho pmid:11979937
Inoue D [Recent advances in research of bone resorption]. 2002 Nippon Rinsho pmid:11979946
Udagawa N and Takahashi N [Possible role of receptor activator of NF-kappa B ligand(RANKL) in osteoclast differentiation and function]. 2002 Nippon Rinsho pmid:11979968
Tsuda E [Osteoclastogenesis inhibitory factor (OCIF)/OPG (a novel therapeutic candidate for the treatment of metabolic bone diseases)]. 2002 Nippon Rinsho pmid:11979969
Koshihara Y [Recent progress of bone cell culture system (review)]. 2002 Nippon Rinsho pmid:11979973
Khosla S et al. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. 2002 J. Clin. Endocrinol. Metab. pmid:11932280
Kanematsu M et al. Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway. 2002 Bone pmid:11934645
Li X et al. Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. 2002 Bone pmid:11934647
Jiang Y et al. Bacteria induce osteoclastogenesis via an osteoblast-independent pathway. 2002 Infect. Immun. pmid:12011008
Granchi D et al. Bone cement extracts modulate the osteoprotegerin/osteoprotegerin-ligand expression in MG63 osteoblast-like cells. 2002 Biomaterials pmid:12013183
Li X et al. Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. 2002 Prostaglandins Other Lipid Mediat. pmid:12013525
Bosshart H Expression of survival receptors in Hodgkin disease cell lines. 2002 Blood pmid:12001908
Ono K et al. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. 2002 J. Bone Miner. Res. pmid:12009007
Iida-Klein A et al. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. 2002 J. Bone Miner. Res. pmid:12009011
Jain RG and Lenhard JM Select HIV protease inhibitors alter bone and fat metabolism ex vivo. 2002 J. Biol. Chem. pmid:11937496
Ariyasu T et al. Trehalose augments osteoprotegerin production in the FHs74Int human intestinal epithelial cell line. 2002 In Vitro Cell. Dev. Biol. Anim. pmid:11963965
Bateman TA and Countryman S Osteoprotegerin and bone loss associated with spaceflight. 2002 Drug Discov. Today pmid:11965392
Price PA et al. Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. 2002 J. Bone Miner. Res. pmid:12096831
Xing L et al. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. 2002 J. Bone Miner. Res. pmid:12096833
Zou W and Bar-Shavit Z Dual modulation of osteoclast differentiation by lipopolysaccharide. 2002 J. Bone Miner. Res. pmid:12096834
Penno H et al. Osteoprotegerin secretion from prostate cancer is stimulated by cytokines, in vitro. 2002 Biochem. Biophys. Res. Commun. pmid:12054622
Fu M et al. Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. 2002 Biochem. Biophys. Res. Commun. pmid:12056809
Kim YH et al. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. 2002 Exp. Mol. Med. pmid:12085990
Khosla S et al. Correlates of osteoprotegerin levels in women and men. 2002 Osteoporos Int pmid:12086350
Ueland T et al. Effects of 12 months of GH treatment on cortical and trabecular bone content of IGFs and OPG in adults with acquired GH deficiency: a double-blind, randomized, placebo-controlled study. 2002 J. Clin. Endocrinol. Metab. pmid:12050246
Sasaki N et al. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. 2002 Bone pmid:12052453
Palenzuela L et al. Familial expansile osteolysis in a large Spanish kindred resulting from an insertion mutation in the TNFRSF11A gene. 2002 J. Med. Genet. pmid:12362049
Fu Q et al. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. 2002 J. Biol. Chem. pmid:12364326
Rogers A et al. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. 2002 J. Clin. Endocrinol. Metab. pmid:12364420
Romas E et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. 2002 Am. J. Pathol. pmid:12368214
Standal T et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. 2002 Blood pmid:12351414
Yang SY et al. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. 2002 Arthritis Rheum. pmid:12355500
Suda T et al. [Merger of bone biology and immunology]. 2002 Tanpakushitsu Kakusan Koso pmid:12385106
Biskobing DM et al. Novel therapeutic options for osteoporosis. 2002 Curr Opin Rheumatol pmid:12118183
Nagasawa T et al. LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. 2002 Clin. Exp. Immunol. pmid:12390325
Lubberts E et al. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. 2002 Arthritis Rheum. pmid:12428250
Kudo O et al. Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. 2002 J. Pathol. pmid:12237882
Hofbauer LC et al. High bone density due to a mutation in LDL-receptor-related protein 5. 2002 N. Engl. J. Med. pmid:12240686
Okada Y et al. Cell-to-Cell adhesion via intercellular adhesion molecule-1 and leukocyte function-associated antigen-1 pathway is involved in 1alpha,25(OH)2D3, PTH and IL-1alpha-induced osteoclast differentiation and bone resorption. 2002 Endocr. J. pmid:12402981
Roodman GD Role of the bone marrow microenvironment in multiple myeloma. 2002 J. Bone Miner. Res. pmid:12412796
Hegedus D et al. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. 2002 J. Bone Miner. Res. pmid:12412803
Zhao S et al. MLO-Y4 osteocyte-like cells support osteoclast formation and activation. 2002 J. Bone Miner. Res. pmid:12412815
Hu Y and Yu S Gene expression of osteoprotegerin and osteoclast differentiation factor in giant cell tumor. 2002 Zhonghua Bing Li Xue Za Zhi pmid:12419159
Sandor M et al. A novel polyethylene depot device for the study of PLGA and P(FASA) microspheres in vitro and in vivo. 2002 Biomaterials pmid:12219832
Shiotani A et al. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. 2002 Anat. Rec. pmid:12221720
Cremer I et al. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. 2002 Blood pmid:12393586
Giuliani N et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. 2002 Blood pmid:12393684
Liao EY et al. Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. 2002 J. Endocrinol. Invest. pmid:12398237
Takahashi E et al. High extracellular calcium affects osteoclastogenesis in mouse bone marrow cell culture. 2002 J. Med. Dent. Sci. pmid:12641381
Ito S et al. Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. 2002 J. Biol. Chem. pmid:11733492
Buckley KA and Fraser WD Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. 2002 Ann. Clin. Biochem. pmid:12564836
Viereck V et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. 2002 Biochem. Biophys. Res. Commun. pmid:11855844
Romas E et al. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. 2002 Bone pmid:11856640
Viereck V et al. Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. 2002 J. Cell. Biochem. pmid:11835398
Wise GE et al. Inhibition of osteoclastogenesis by the secretion of osteoprotegerin in vitro by rat dental follicle cells and its implications for tooth eruption. 2002 Arch. Oral Biol. pmid:11839361
Faucheux C et al. Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: evidence for parathyroid hormone-related protein and receptor activator of NF-kappaB-dependent effects on osteoclast formation in regenerating mammalian bone. 2002 J. Bone Miner. Res. pmid:11874237
Kazama JJ et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. 2002 Am. J. Kidney Dis. pmid:11877571
Haas M et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. 2002 Am. J. Kidney Dis. pmid:11877577
Goater JJ et al. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. 2002 J. Orthop. Res. pmid:11918293
Kazama JJ et al. Circulating osteoprotegerin is not removed through haemodialysis membrane. 2002 Nephrol. Dial. Transplant. pmid:12271009
Roux S et al. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. 2002 Br. J. Haematol. pmid:11918537
Lee SW et al. TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB. 2002 J. Biochem. Mol. Biol. pmid:12296995
Oshiro T et al. Osteoclast induction in periodontal tissue during experimental movement of incisors in osteoprotegerin-deficient mice. 2002 Anat. Rec. pmid:11920384
Redlich K et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. 2002 Arthritis Rheum. pmid:11920416
Cho CH and Nuttall ME Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases. 2002 Expert Opin. Ther. Targets pmid:12472380
Hasegawa T et al. Expression of receptor activator of NF-kappa B ligand and osteoprotegerin in culture of human periodontal ligament cells. 2002 J. Periodont. Res. pmid:12472833
Yamashita T et al. Double mutations in klotho and osteoprotegerin gene loci rescued osteopetrotic phenotype. 2002 Endocrinology pmid:12446599
Yang X et al. Protein Kinase C is a mediator of the synthesis and secretion of osteoprotegerin in osteoblast-like cells. 2002 Biochem. Biophys. Res. Commun. pmid:11779130
Nosaka K et al. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. 2002 Blood pmid:11781248
Bolon B et al. Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. 2002 Cell. Mol. Life Sci. pmid:12440777
David JP et al. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. 2002 J. Cell. Sci. pmid:12376563
Jones DH et al. Role of RANKL and RANK in bone loss and arthritis. 2002 Ann. Rheum. Dis. pmid:12379618
Gravallese EM Bone destruction in arthritis. 2002 Ann. Rheum. Dis. pmid:12379632
Spyrou P et al. Cytokine release by osteoblast-like cells cultured on implant discs of varying alloy compositions. 2002 Clin Oral Implants Res pmid:12519337
Berenson JR Advances in the biology and treatment of myeloma bone disease. 2002 Semin. Oncol. pmid:12520479
Woo KM et al. Osteoprotegerin is present on the membrane of osteoclasts isolated from mouse long bones. 2002 Exp. Mol. Med. pmid:12526098
Bengtsson AK and Ryan EJ Immune function of the decoy receptor osteoprotegerin. 2002 Crit. Rev. Immunol. pmid:12498383

Table of Content